Nothing Special   »   [go: up one dir, main page]

AR067575A1 - Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico - Google Patents

Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico

Info

Publication number
AR067575A1
AR067575A1 ARP080103068A ARP080103068A AR067575A1 AR 067575 A1 AR067575 A1 AR 067575A1 AR P080103068 A ARP080103068 A AR P080103068A AR P080103068 A ARP080103068 A AR P080103068A AR 067575 A1 AR067575 A1 AR 067575A1
Authority
AR
Argentina
Prior art keywords
different
same
nrr
hal
aryl
Prior art date
Application number
ARP080103068A
Other languages
English (en)
Inventor
Laurence Gauzy
Ravi V J Chari
Herve Bouchard
Yonghong Deng
Alain Commercon
Original Assignee
Liao Wenhui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39048765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067575(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liao Wenhui filed Critical Liao Wenhui
Publication of AR067575A1 publication Critical patent/AR067575A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente se refiere a nuevos derivados de tomaimicina que comprenden un ligante. También se refiere a las moléculas de conjugado que comprenden uno o más de dichos derivados de tomaimicina unidos mediante enlaces covalentes a un agente de union a la célula por un grupo de enlace que está presente en el ligante del derivado de tomaimicina. También se refiere a la preparacion de los derivados de tomaimicina y de las moléculas de conjugado. Composicion farmacéutica y uso para preparar medicamentos para tratar cáncer. Reivindicacion 1: Compuesto de formula (1) en la que: ----- representa un enlace sencillo opcional; ------ representa o un enlace sencillo o un doble enlace; siempre que cuando ------ represente un enlace sencillo, U y U', iguales o diferentes, representan independientemente H y W y W', iguales o diferentes, se seleccionan independientemente del grupo que consiste en: -OH, -OR, -OCOR, -COOR, -OCOOR, -OCONRR', un carbamato cíclico tal que N10 y C11 son una parte del ciclo, -NRCONRR', -OCSNHR, un tiocarbamato cíclico tal que N10 y C11 son una parte del ciclo, -SH, -SR, - SOR, -SOOR,-SO3, -NRSOOR', -NRR', una amina cíclica tal que N10 y C11 son una parte del ciclo, -NROR', -NRCOR', -N3, -CN, Hal, un trialquilo o triarilfosfonio y cuando ----- represente un doble enlace, U y U' están ausentes y W y W' representan H; R1, R2, R1', R2' son iguales. o diferentes y se eligen independientemente de: H, haluro o alquilo opcionalmente sustituido por uno o más Hal, CN, NRR', CF3, OR, arilo, Het; S(O)qR o R1 y R2 y R1' y R2' forman juntos un doble enlace que contiene grupo =B y =B' respectivamente; B y B' son iguales o diferentes y se eligen independientemente de: alquenilo que está opcionalmente sustituido por uno o más: Hal, CN, NRR', CF3, OR, SR, SOR, SO2R, arilo, Het o B y B' representan un átomo de oxígeno; X, X' son iguales o diferentes y se eligen independientemente de uno o más: -O-, -S-, -NR, -(C=O)-, -SO-, -SO2-, A, A' son iguales o diferentes y se eligen independientemente de alquilo o alquenilo, estando cada uno opcionalmente sustituido por uno o más: Hal, CN, NRR', CF3, OR, SR, SOR, SO2R, arilo, Het, alquilo, alquenilo; Y, Y' son iguales o diferentes y se eligen independientemente entre H, OR; T es -NR- o un arilo de 4 a 10 miembros, cicloalquilo, heterociclo, heteroarilo o un alquilo lineal o ramificado, estando cada uno sustituido por uno o más ligados no escindibles y opcionalmente sustituidos por uno o más de: Hal, CN, NRR', CF3, R, OR, SOR o SO2R; n, n', iguales o diferentes, son 0 o 1; q es 0,1 o 2; R, R' son iguales o diferentes y se eligen independientemente de: H, alquilo, arilo, estando cada uno opcionalmente sustituido por: Hal, CN, COOH, COOR, CONHR, CONRR', NRR', CF3, R, OR, SOR, SO2R, arilo, Het, o las sales farmacéuticamente aceptables, hidratos o sales hidratadas, las estructuras cristalinas polimorficas o sus isomeros opticos, racematos, diastereoisomeros o enantiomeros, de dichos compuestos.
ARP080103068A 2007-07-19 2008-07-17 Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico AR067575A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07290904.7A EP2019104B1 (en) 2007-07-19 2007-07-19 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use

Publications (1)

Publication Number Publication Date
AR067575A1 true AR067575A1 (es) 2009-10-14

Family

ID=39048765

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103068A AR067575A1 (es) 2007-07-19 2008-07-17 Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico

Country Status (40)

Country Link
US (1) US8404678B2 (es)
EP (2) EP2019104B1 (es)
JP (1) JP5551070B2 (es)
KR (1) KR101627871B1 (es)
CN (1) CN101784550B (es)
AR (1) AR067575A1 (es)
AT (1) ATE530553T1 (es)
AU (1) AU2008281439B2 (es)
BR (1) BRPI0814267A2 (es)
CA (1) CA2693551C (es)
CL (1) CL2008002139A1 (es)
CO (1) CO6290692A2 (es)
CR (1) CR11225A (es)
CY (2) CY1112278T1 (es)
DK (2) DK2019104T3 (es)
DO (1) DOP2010000014A (es)
EA (1) EA019938B1 (es)
EC (1) ECSP109875A (es)
ES (2) ES2435779T3 (es)
GT (1) GT201000008A (es)
HK (1) HK1144289A1 (es)
HR (1) HRP20120067T1 (es)
IL (1) IL203318A (es)
JO (1) JO2744B1 (es)
MA (1) MA31617B1 (es)
ME (1) ME00969B (es)
MY (1) MY151245A (es)
NI (1) NI201000005A (es)
NZ (1) NZ582679A (es)
PA (1) PA8790201A1 (es)
PE (2) PE20090889A1 (es)
PL (2) PL2019104T3 (es)
PT (2) PT2019104E (es)
RS (1) RS52245B (es)
SI (2) SI2019104T1 (es)
TN (1) TN2010000002A1 (es)
TW (1) TWI500618B (es)
UA (1) UA98153C2 (es)
WO (1) WO2009016516A2 (es)
ZA (1) ZA201000389B (es)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399609B1 (en) 2005-08-24 2015-03-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2009014910A2 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
DE102008056086A1 (de) * 2008-11-06 2010-05-12 Gp Solar Gmbh Additiv für alkalische Ätzlösungen, insbesondere für Texturätzlösungen sowie Verfahren zu dessen Herstellung
CN108727407B (zh) 2009-02-05 2022-01-28 伊缪诺金公司 新型苯并二氮杂䓬衍生物
AU2015224492B2 (en) * 2009-02-05 2017-04-20 Immunogen, Inc. Novel benzodiazepine derivatives
EP3480202A1 (en) 2009-06-03 2019-05-08 ImmunoGen, Inc. Conjugation methods
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
US9242013B2 (en) 2010-04-15 2016-01-26 Seattle Genetics Inc. Targeted pyrrolobenzodiazapine conjugates
BR112012026410B8 (pt) 2010-04-15 2023-01-31 Spirogen Dev Sarl Composto e conjugado de pirrolobenzodiazepinas e usos dos mesmos
CA2793890C (en) * 2010-04-15 2017-08-15 Spirogen Developments Sarl Pyrrolobenzodiazepines and conjugates thereof
CN109674753A (zh) 2010-06-23 2019-04-26 希玛贝治疗股份有限公司 固态分散体
FR2963007B1 (fr) * 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
AU2012217719B2 (en) * 2011-02-15 2015-11-05 Immunogen, Inc. Methods of preparation of conjugates
KR20220009505A (ko) 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
MX341524B (es) 2011-09-20 2016-08-24 Medimmune Ltd Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos.
CN110183470A (zh) 2011-10-14 2019-08-30 麦迪穆有限责任公司 吡咯并苯并二氮杂卓
MX358757B (es) 2011-10-14 2018-09-03 Seattle Genetics Inc Pirrolobenzodiazepinas y conjugados dirigidos.
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9399073B2 (en) 2011-10-14 2016-07-26 Seattle Genetics, Inc. Pyrrolobenzodiazepines
BR112014014464A2 (pt) * 2011-12-13 2017-06-13 Immunogen Inc uso de n-hidroxisuccinimida para melhorar a estabilidade do conjugado
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
MX2014012889A (es) 2012-05-01 2014-11-14 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17.
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
ES2643225T3 (es) 2012-07-09 2017-11-21 Genentech, Inc. Inmunoconjugados que comprenden anticuerpos anti-CD79b
AU2013288929A1 (en) 2012-07-09 2014-12-04 Genentech, Inc. Immunoconjugates comprising anti-CD22 antibodies
WO2014022679A2 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
CN105209592A (zh) 2012-10-04 2015-12-30 伊缪诺金公司 使用pvdf膜纯化细胞结合剂细胞毒性剂缀合物
CN105050661B (zh) 2012-10-12 2018-03-30 Adc疗法责任有限公司 吡咯并苯并二氮杂卓‑抗体结合物
JP6367204B2 (ja) 2012-10-12 2018-08-01 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 結合用のピロロベンゾジアゼピン誘導体の合成および中間体
LT2906248T (lt) 2012-10-12 2019-02-11 Medimmune Limited Pirolobenzodiazepinai ir jų konjugatai
EA035405B1 (ru) 2012-10-12 2020-06-08 Медимьюн Лимитед Пирролбензодиазепины и их конъюгаты
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
BR112015008232A2 (pt) 2012-10-12 2017-12-05 Adc Therapeutics Sarl conjugados pirrolbenzodiazepina-anticorpo
HUE041274T2 (hu) 2012-10-12 2019-05-28 Adc Therapeutics Sa Pirrolobenzodiazepin-anti-PSMA-antitest konjugátumok
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pirrolobenzodiazepine anti-CD22 antibody conjugates
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
KR102066318B1 (ko) * 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
ES2702181T3 (es) 2013-03-13 2019-02-27 Seattle Genetics Inc Filtración con carbono activado para la purificación de ADC de benzodiazepina
JP6445519B2 (ja) * 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
AU2014244424A1 (en) 2013-03-14 2015-08-27 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3046940B1 (en) 2013-09-17 2019-07-03 F.Hoffmann-La Roche Ag Methods of using anti-lgr5 antibodies
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
TW201533060A (zh) 2013-12-13 2015-09-01 Genentech Inc 抗ｃｄ３３抗體及免疫結合物
EP3082876B1 (en) 2013-12-16 2018-01-17 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3122757B1 (en) 2014-02-28 2023-09-06 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
RU2016150370A (ru) 2014-05-22 2018-06-26 Дженентек, Инк. Антитела и иммуноконъюгаты против GPC3
ES2913865T3 (es) 2014-08-28 2022-06-06 Bioatla Inc Receptores de antígeno quimérico condicionalmente activos para células T modificadas
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
PT3189056T (pt) 2014-09-03 2020-09-04 Immunogen Inc Derivados citotóxicos de benzodiazepina
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
CN114106185A (zh) 2014-09-12 2022-03-01 基因泰克公司 抗her2抗体和免疫缀合物
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN107001465B (zh) 2014-09-12 2020-12-11 基因泰克公司 抗-cll-1抗体和免疫缀合物
MX2017003472A (es) * 2014-09-17 2017-10-31 Genentech Inc Inmunoconjugados que comprenden anticuerpos anti-her2.
NZ731782A (en) * 2014-11-25 2023-04-28 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
KR20170102980A (ko) 2015-01-14 2017-09-12 브리스톨-마이어스 스큅 컴퍼니 벤조디아제핀 이량체, 그의 접합체, 및 제조 및 사용 방법
AU2016206808A1 (en) 2015-01-14 2017-08-31 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CN108391434A (zh) 2015-06-23 2018-08-10 百时美施贵宝公司 大环苯并二氮杂*二聚体、其缀合物、制备和用途
JP6759326B2 (ja) 2015-07-12 2020-09-23 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 細胞結合分子の共役のための架橋連結体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN108026103B (zh) 2015-07-21 2021-04-16 伊缪诺金公司 制备细胞毒性苯并二氮杂䓬衍生物的方法
EP4477269A2 (en) 2015-09-20 2024-12-18 The United States of America, as Represented By the Secretary, Department of Health and Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
CN107405408B (zh) * 2015-12-21 2021-07-02 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
KR20200087875A (ko) 2016-04-15 2020-07-21 바이오아트라, 엘엘씨 항 Axl항체 및 이의 면역접합체와 이것들의 용도
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
CN116751298A (zh) 2016-05-13 2023-09-15 生物蛋白有限公司 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN107469089B (zh) * 2016-06-07 2022-01-07 北京键凯科技股份有限公司 一种peg连接子及配基药物偶联物
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
EP3494135A1 (en) 2016-08-02 2019-06-12 The United States of America, as represented by The Secretary, Department of Health and Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
JP2019527693A (ja) 2016-08-03 2019-10-03 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3042442C (en) 2016-11-14 2024-01-02 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers
AU2017361887B2 (en) 2016-11-21 2019-08-15 Cureab Gmbh Anti-GP73 antibodies and immunoconjugates
EP3544983A2 (en) 2016-11-23 2019-10-02 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
WO2018119279A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
EP3558391B1 (en) 2016-12-23 2022-02-02 Immunogen, Inc. Immunoconjugates targeting adam9 and methods of use thereof
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
HUE054689T2 (hu) 2017-02-08 2021-09-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3612537T (pt) 2017-04-18 2022-08-29 Medimmune Ltd Conjugados de pirrolobenzodiazepina
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
EP3625256A1 (en) 2017-05-19 2020-03-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
ES2988683T3 (es) 2017-06-14 2024-11-21 Adc Therapeutics Sa Pautas posológicas para la administración de un CAF anti-CD19
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
BR112020003003A2 (pt) 2017-08-18 2020-08-11 Medimmune Limited conjugados de pirrolobenzodiazepina
CA3126646A1 (en) 2017-09-29 2019-04-04 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
JP2021508714A (ja) 2017-12-28 2021-03-11 イミュノジェン・インコーポレーテッド ベンゾジアゼピン誘導体
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3820903A1 (en) 2018-07-12 2021-05-19 The United States of America, as represented by the Secretary, Department of Health and Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
CA3106544A1 (en) 2018-08-08 2020-02-13 Mitchell Ho High affinity monoclonal antibodies targeting glypican-2 and uses thereof
TW202029980A (zh) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
IL312067A (en) 2018-12-21 2024-06-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
JP7542266B2 (ja) * 2019-01-03 2024-08-30 リガケム バイオサイエンシズ， インク． 安定性が向上したピロロベンゾジアゼピン二量体化合物及びその用途
WO2020146182A1 (en) 2019-01-08 2020-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
EP3883971A1 (en) 2019-01-22 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2020187721A1 (en) 2019-03-15 2020-09-24 Medimmune Limited Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
CN113661172A (zh) 2019-03-29 2021-11-16 伊缪诺金公司 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
EP4031250A1 (en) 2019-10-22 2022-07-27 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
AU2020402752A1 (en) 2019-12-12 2022-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for CD276 and uses thereof
CA3172111A1 (en) 2020-03-19 2021-09-23 Barbora MALECOVA Compositions and methods of treating facioscapulohumeral muscular dystrophy
KR20220161378A (ko) 2020-03-27 2022-12-06 어비디티 바이오사이언시스 인크. 근이영양증의 치료용 조성물 및 방법
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
US20240218055A1 (en) 2021-04-29 2024-07-04 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
WO2022261017A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
JP2024535797A (ja) 2021-09-16 2024-10-02 アビディティー バイオサイエンシーズ，インク． 顔面肩甲上腕型筋ジストロフィーを処置する組成物および方法
JP2024544508A (ja) 2021-11-09 2024-12-03 トゥルーバインディング，インコーポレイテッド 心臓血管疾患を治療または阻害する方法
TW202406934A (zh) 2022-05-03 2024-02-16 美商建南德克公司 抗Ｌｙ６Ｅ抗體、免疫結合物及其用途
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
ATE294803T1 (de) 1998-08-27 2005-05-15 Spirogen Ltd Pyrrolobenzodiazepine
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
JP2003514903A (ja) 1999-11-24 2003-04-22 イムノージェン インコーポレーテッド タキサンを含有する細胞傷害薬とその治療への利用
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
WO2004087716A1 (en) * 2003-03-31 2004-10-14 Council Of Scientific And Industrial Research Pyrrolo[(2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
WO2004091542A2 (en) 2003-04-15 2004-10-28 Covx Pharmaceuticals, Inc. Nitrogen containing integrin targeting compounds
KR101565721B1 (ko) 2003-07-21 2015-11-03 이뮤노젠 아이엔씨 씨에이6 항원 특이적 세포독성 접합체 및 이를 사용하는 방법
GB0321295D0 (en) * 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
CA2543318C (en) 2003-10-22 2013-01-08 B. Rao Vishnuvajjala Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
GB0404578D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
WO2005085260A1 (en) 2004-03-09 2005-09-15 Spirogen Limited Pyrrolobenzodiazepines
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
PT1813614E (pt) * 2006-01-25 2012-01-09 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina
CN101622276B (zh) * 2006-07-18 2015-04-22 赛诺菲-安万特 用于治疗癌症的抗epha2的拮抗抗体
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
AU2008281439A1 (en) 2009-02-05
HK1144289A1 (en) 2011-02-11
CN101784550A (zh) 2010-07-21
IL203318A (en) 2016-08-31
KR20100063021A (ko) 2010-06-10
TN2010000002A1 (en) 2011-09-26
CY1114922T1 (el) 2016-12-14
DK2019104T3 (da) 2013-12-16
ECSP109875A (es) 2010-02-26
PT2170890E (pt) 2012-02-03
ES2435779T3 (es) 2013-12-23
WO2009016516A3 (en) 2009-06-11
US20100316656A1 (en) 2010-12-16
ATE530553T1 (de) 2011-11-15
PT2019104E (pt) 2013-12-03
EP2170890A2 (en) 2010-04-07
PA8790201A1 (es) 2009-02-09
NI201000005A (es) 2010-03-09
CR11225A (es) 2010-06-23
PE20130590A1 (es) 2013-05-22
JO2744B1 (en) 2014-03-15
ES2376026T3 (es) 2012-03-08
NZ582679A (en) 2012-04-27
TWI500618B (zh) 2015-09-21
CA2693551C (en) 2016-09-20
JP5551070B2 (ja) 2014-07-16
TW200922598A (en) 2009-06-01
JP2010533703A (ja) 2010-10-28
CO6290692A2 (es) 2011-06-20
ZA201000389B (en) 2011-04-28
MA31617B1 (fr) 2010-08-02
DOP2010000014A (es) 2010-02-15
AU2008281439B2 (en) 2013-02-07
DK2170890T3 (da) 2012-02-27
CN101784550B (zh) 2014-06-11
WO2009016516A8 (en) 2009-04-16
RS52245B (en) 2012-10-31
SI2170890T1 (sl) 2012-02-29
SI2019104T1 (sl) 2013-12-31
BRPI0814267A2 (pt) 2015-03-31
EP2019104A1 (en) 2009-01-28
US8404678B2 (en) 2013-03-26
CA2693551A1 (en) 2009-02-05
EA019938B1 (ru) 2014-07-30
PL2019104T3 (pl) 2014-03-31
WO2009016516A2 (en) 2009-02-05
PE20090889A1 (es) 2009-08-06
HRP20120067T1 (hr) 2012-02-29
EP2170890B1 (en) 2011-10-26
EP2019104B1 (en) 2013-09-04
MY151245A (en) 2014-04-30
PL2170890T3 (pl) 2012-04-30
ME00969B (me) 2012-06-20
CL2008002139A1 (es) 2009-10-23
KR101627871B1 (ko) 2016-06-07
GT201000008A (es) 2012-03-26
UA98153C2 (uk) 2012-04-25
CY1112278T1 (el) 2015-12-09
EA201070163A1 (ru) 2010-08-30

Similar Documents

Publication Publication Date Title
AR067575A1 (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR059201A1 (es) Compuestos citotoxicos derivados de tomaimicina
AR058293A1 (es) Sales profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]pirimidin-5-carbonil)-2-metoxi-fenil]-3-(2,4-dicloro-fenil)-urea
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
AR045761A1 (es) Derivados de 2-piridona como inhibidores de elastasa de neutrofilos
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR084768A1 (es) Moduladores de la senda de complemento y usos de los mismos
AR039659A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa
HRP20150273T1 (hr) Spojevi bis(floroalkil)-1,4-benzodiazepinona
ECSP10010178A (es) Derivados bis-(sulfonilamino) en terapia 066
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR086676A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
DOP2006000243A (es) Derivados de pirazina
HRP20110156T1 (hr) Monociklički heterocikli kao inhibitori kinaze
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
HRP20150954T1 (hr) Derivati dialkoksikinazolina kao inhibitori kdr
AR065531A1 (es) Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas.
AR061185A1 (es) Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
AR061792A1 (es) Derivados heterociclicos y su uso en el tratamiento o prevencion de enfermedades psiquiatricas donde se requiere un aumento de las respuestas sinapticas mediadas por receptores ampa
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR081966A1 (es) Derivados aminoester de alcaloides y composicion medicinal de los mismos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee